recent advances in mhspc: 177lu-psma-617, propel and biomarker-directed strategies
Published 2 years ago • 67 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
11:01
lutetium-177: psma guided treatment | #prostatecancer | #markscholzmd | #pcri
-
0:57
real-world outcomes of 177lu-psma-617 in mcrpc
-
1:08
psma imaging pre- and post-177lu-psma-617 treatment in mcrpc
-
11:58
prostic24 - louise emmett: restaging in metastatic disease with psma pet/ct in prostate cancer
-
4:55
3 future prostate cancer treatment advancements | mark scholz, md & mark moyad, md | 2021 pcri
-
10:07
new fda approved: pluvicto (lutetium-177) for advanced prostate cancer | mark scholz, md | pcri
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
4:48
vision: lu-177-psma-617 in mcrpc
-
5:45
efficacy and toxicity of 177lu-psma-617 for mcrpc in a real-world setting
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
1:24
luparp: 177lu-psma-617 and parp inhibitor combination for prostate cancer
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
3:17
safety and efficacy of 177lu-psma-617
-
1:17
prince: 177lu-psma-617 and pembrolizumab in prostate cancer
-
4:41
lutetium-177–psma-617 improves self-reported pain and hrqol in taxane-naïve patients with psma-p...
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
5:06
efficacy of lutetium-177–psma-617 for advanced prostate cancer
-
1:02
dr. gafita on prognostic models for treatment with 177lu-psma-617 in mcrpc
-
3:07
psma-trt, 225ac-j591 and 177lu-psma i&t in mcrpc